Press Release Archive
-
Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention
-
Dr. Paul Janssen Award for Biomedical Research Issues 2019 Call for Nominations to Celebrate Champions of Science
-
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2019
-
Johnson & Johnson to Participate in 37th Annual JP Morgan Health Care Conference
-
Johnson & Johnson to Host
Investor Conference Call on Fourth-Quarter Results -
Johnson & Johnson Announces $5 Billion Share Repurchase Program
-
Statement on Reuters Talc Article
-
Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients
-
Janssen Signs Results-Based Contract with Oklahoma Health Care Authority (OHCA) for its Long-Acting Injectable Schizophrenia Medicines
-
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48